Dr. Hemminki has authored nearly 300 peer-reviewed manuscripts or book chapters on cancer research and oncolytic viruses.
Some recent notable examples of scientific publications include:
- Phase I results on TILT-123 dose escalation as monotherapy (TILT-T115)
- TILT-123 in ovarian cancer human samples
- Review on oncolytic adenovirus selectivity and MoA
- TILT technology to replace high dose IL-2 conditioning
- Anti-PD-1 + TILT tech
- Anti-PDL1 + TILT tech
- TILT technology to replace lymphocyte depleting chemotherapy
- Collaboration with CAR T UPENN team
- TILT-123 seminal paper
- Predictive and prognostic clinical variables in cancer patients treated with adenoviral oncolytic immunotherapy
- Adenoviruses systemic spread
- TILT-123 prototype in 13 cancer patients
